For research use only. Not for therapeutic Use.
CMS-121 is a quinolone derivative and an orally active acetyl-CoA carboxylase 1 (ACC1) inhibitor. CMS-121 protects HT22 cells against ischemia and oxidative damage with EC50 values of 7 nM and 200 nM, respectively. CMS-121 has strong neuroprotective, anti-inflammatory, antioxidative and renoprotective activities[1][2][3].
CMS-121 (1 µM; 4 hours; HT22 cells) treatment increases the phosphorylation of ACC1 at serine 79. CMS-121 can increase acetyl-CoA in cells[1].
CMS-121 (~20 mg/kg; oral administration; daily; for 4 months; female SAMP8 mice) treatment reduces cognitive decline as well as metabolic and transcriptional markers of aging in the brain when administered to rapidly aging SAMP8 mice. CMS-121 preserves mitochondrial homeostasis by regulating acetyl-coenzyme A (acetyl-CoA) metabolism[1].
| Catalog Number | I016166 |
| CAS Number | 1353224-53-9 |
| Synonyms | 4-(4-cyclopentyloxyquinolin-2-yl)benzene-1,2-diol |
| Molecular Formula | C20H19NO3 |
| Purity | ≥95% |
| InChI | InChI=1S/C20H19NO3/c22-18-10-9-13(11-19(18)23)17-12-20(24-14-5-1-2-6-14)15-7-3-4-8-16(15)21-17/h3-4,7-12,14,22-23H,1-2,5-6H2 |
| InChIKey | OMHNVUCFPJJLKD-UHFFFAOYSA-N |
| SMILES | C1CCC(C1)OC2=CC(=NC3=CC=CC=C32)C4=CC(=C(C=C4)O)O |
| Reference | [1]. Currais A, et al. Elevating acetyl-CoA levels reduces aspects of brain aging. Elife. 2019 Nov 19;8. pii: e47866. [2]. Chiruta C, et al. Chemical modification of the multitarget neuroprotective compound fisetin. J Med Chem. 2012 Jan 12;55(1):378-89. [3]. Prior M, et al. Back to the future with phenotypic screening. ACS Chem Neurosci. 2014 Jul 16;5(7):503-13. |
